Category

New

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By | Eprint, New

Esther Serra, Cristina Campo, Zoltan Novak, Bernadetta Majorek-Olechowska, Grazyna Pulka, Aintzane García-Bea and Luis Labeaga

Pruritus is a common symptom associated with different skin diseases, including urticaria, atopic dermatitis, eczema and prurigo. Pruritus may have a significant impact on the quality of life and psychosocial wellbeing of patients with skin urticaria. Bilastine is a H1-antihistamine with demonstrable efficacy for the symptomatic treatment of chronic spontaneous urticaria.

 

A phase IV, multicentre, open-label, exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases was conducted at 10 European Centres.

 

115 patients between 18 and 74 years diagnosed with chronic spontaneous urticaria, eczema/dermatitis, prurigo or cutaneous pruritus who had not responded to placebo during a run-in period of 7-14 days and with, at least 4 points for the sum of itch score during the last 3 days of the run-in period were included. Patients received bilastine 20 mg once daily for 8 weeks and non-responders (<30% improvement in pruritus score at week 2), received 40 mg daily from week 2.

 

Bilastine reduced the mean change in weekly pruritus severity score from baseline to week 8 (primary endpoint) (overall and by disease group). Up dosed non-responders (n = 31) improved weekly pruritus severity scores from baseline to week 8. Bilastine improved the Dermatology Life Quality Index at weeks 4 and 8 (p < 0,001) in all disease groups, and the 7-day Urticaria Activity Score in CSU patients (p <0 ,001).

 

In conclusion, bilastine has demonstrated efficacy for the relief of pruritus associated with urticaria and other skin diseases in adults, with a very good safety profile. Also, bilastine up dosing to 40mg (double dose), for patients who did not achieve a significant improvement after 2 weeks of treatment, was efficacious without any safety concerns.

This document is only available for registered healthcare professionals.

login
La urticaria crónica (CUR) contribuye a la comprensión y el conocimiento de la enfermedad en la región.

Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region

By | Artículos seleccionados, New, Selected articles

Gómez RM, Jares E, Borges MS, Baiardini I, Canonica GW, Passalacqua G, Kaplan A, Latour P, Costa E, Dias G, Lavrut J; SLAAI CUR group.

Chronic urticaria (CU) has a widespread spectrum on causal or exacerbating factors, clinical manifestations, therapeutic response and quality of life affectation. Registries are useful tools in several real-life diagnosis and management approach.We aimed to evaluate the characteristics of CU patients living in Latin America through an original cross-sectional registry with data entered by regional allergologists.

This document is only available for registered healthcare professionals.

login
The Role of Mobile Health Technologies in Allergy Care: an EAACI Position Paper.

The Role of Mobile Health Technologies in Allergy Care: an EAACI Position Paper

By | Artículos seleccionados, New, Selected articles

Matricardi PM, (…)

Mobile Health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health-related services, data flow and information, patient self-management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology.

This document is only available for registered healthcare professionals.

login
Diagnosis and treatment of urticaria in primary care

Diagnosis and treatment of urticaria in primary care

By | Artículos seleccionados, New, Selected articles

Kayiran MA, Akdeniz N.

Urticaria, also known as hives among people, is a very common disease characterized by erythematous, edematous, itchy, and transient plaques that involve skin and mucous membranes. It is classified as acute spontaneous urticaria, chronic spontaneous urticaria, chronic inducible urticaria, and episodic chronic urticaria. Many factors such as infections, medicines, food, psychogenic factors, and respiratory allergens are accused of etiology, but sometimes, it is idiopathic. Clinical presentation involves red, swelling, and itchy plaques. The lesions usually resolve spontaneously within 2-3 h without a trace.

This document is only available for registered healthcare professionals.

login
Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis

Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis

By | Artículos seleccionados, New, Selected articles

Pantin CT, Southworth T, Wetzel K, Singh D.

Allergic rhinitis is characterized by nasal inflammation that occurs in response to allergen exposure. Reproducibility of nasal secretion cytokine responses and physiological measurements are needed to determine the optimum measurements and power calculations for future studies. A group of investigators have investigated the reproducibility of nasal cytokine measurements, using ready-to-use polyvinyl acetate sponges to collect nasal secretions, and measurements of nasal physiological responses.

This study included twelve participants with allergic rhinitis and no history of respiratory disease, and twelve with asthma and allergic rhinitis. They were submitted to a nasal allergen challenge which was repeated 7-14 days later. Participants had an increase in IL-5, and in cytokines CCL11 and CXCL8 responses post-challenge (all P<0.05). Acoustic rhinometry provided good to excellent reproducibility and rhinomanometry had lower reproducibility with greater variation, with some participants unable to perform the measurement. Multiplex immunoassays provided greater sensitivity for cytokine CCL11 measurements. There were no differences between allergic rhinitis patients with and without asthma.

They concluded that polyvinyl acetate sponges are a practical and reproducible way to sample nasal secretions and acoustic rhinometry is a practical and reproducible method for assessing physiological responses

This document is only available for registered healthcare professionals.

login
Treatment of urticaria: a clinical and mechanistic approach

Treatment of urticaria: a clinical and mechanistic approach

By | Artículos seleccionados, New, Selected articles

Kaplan AP.

Urticaria can be divided into three general subtypes. Acute urticaria is defined as urticaria of relatively short duration that can be as brief as a day or two or can last up to 6 weeks. “Physical urticarias or inducible urticarias” consist of cold urticaria, cholinergic urticaria, and dermatographism as the most common, plus solar urticaria, local heat urticaria, aquagenic urticaria, vibratory urticaria/angioedema, and delayed pressure urticaria. The third subtype is chronic spontaneous urticaria (CSU) where the urticaria is present for over a minimum of 6 weeks up to many years.

Antihistamines are effective in about 50% of patients with CSU by interacting with the H1 receptor rendering it unresponsive to histamines. Omalizumab is effective in 65–80% of antihistamine-resistant patients and acts by binding IgE, thereby eliminating IgE directed to an autoantigen, downregulating IgE receptors, so that antireceptor antibodies are blocked, and ultimately leading to unresponsiveness of cutaneous mast cells and basophils. The addition of omalizumab represents a major advance because of its efficacy, easy utility, and favourable side-effect profile. Cyclosporine inhibits not only T cells but also histamine release from basophils and mast cells, has a success rate of about 70%, and is recommended third-line with care directed to potential side effects affecting blood pressure and renal function.

In conclusion, the use of antihistamines in high dosage (at least four times a day) is effective in close to half the patients with chronic spontaneous urticaria. For antihistamine resistance, the use of omalizumab has revolutionized therapy of antihistamine-resistant cases because of its efficacy and excellent side-effect profile. If the response is insufficient, cyclosporine is the next choice. Patients should be monitored regarding any adverse effects on blood pressure or renal function. All these are far safer than extended use of corticosteroid.

This document is only available for registered healthcare professionals

Login
Second generation antihistamines: an update

Second generation antihistamines: an update

By | Artículos seleccionados, New, Selected articles

Allergic rhinoconjuntivitis, rhinitis and urticaria are major health problems that affect a sizable portion of the population of all ages, interfering with quality of life and resulting in an important burden for the health system.

First generation antihistamines have major unwanted effects, including sedation, weight gain and anticholinergic effects. Second generation H1-antihistamines (SGAHs) are free from the unacceptable side effects of the first-generation ones and are now preferred by physicians and patients as first line therapies.

SGAHs have a good absorption profile, whenever administered orally, with effective plasma concentrations being reached in most of them within 3 hours after dosing. Their liposolubility permits the crossing of cell membranes, helping their bioavailability.

Regarding their metabolism and elimination, H1-antihistamines bind to transporter plasmatic proteins, with plasma protein binding varying from 60 to 95%. The higher plasma protein binding, the less persistent antihistamine effects. Benzodiazepines may decrease H1-antihistamines plasma concentrations. Macrolides, antifungals and calcium antagonists may increase plasmatic concentrations.

H1-antihistamines are well tolerated for allergic rhinoconjunctivitis at the usual dosage. In respect to urticaria, their efficacy is attributed to their H1-antihistaminic activity on small unmyelinated afferent C-fibers to reduce itching, on axonic reflexes to reduce erythema and on the endothelial cells of the post-capillary venules to reduce extravasion and wheal formation. Most H1-antihistamines appear to have anti-inflammatory effects including the reduction of production of preformed and neoformed mediators, cytokines, chemokines and adherence molecules, inflammatory cell recruitment and inflammation in general.

This article summarizes an update on the clinical pharmacology, mechanisms of action and safety of the second-generation antihistamines.

bilastina alivia prurito

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By | Articles about Bilastine, New

Serra E, Campo C, Novák Z, Majorek-Olechowska B, Pulka G, García-Bea A, Labeaga L.

PURPOSE: To evaluate the efficacy/safety of bilastine in pruritus relief in patients with chronic spontaneous urticaria (CSU) or other pruritic skin diseases.

CONCLUSIONS: Bilastine relieved pruritus associated with urticaria and other skin diseases, with a very good safety profile.

This document is only available for registered healthcare professionals

Login
Bilastina y anticuerpos anti-

The real-life effectiveness and safety of omalizumab updosing in patients with chronic spontaneous urticaria

By | Articles about Bilastine, New

Andac Salman and Elif Comert

(2019) Journal of Cutaneous Medicine and Surgery

A retrospective cohort study was conducted to investigate the effectiveness and safety of 450 mg of omalizumab in chronic spontaneous urticaria.

Omalizumab is a third-line treatment for chronic spontaneous urticaria, however there are not enough studies regarding its use in patients that are unresponsive to regular doses of omalizumab.

A total of 72 patients were included, according to their Urticaria Activity Score over 7 days and the Urticaria Control Test and divided in two groups. Group 1 (n=59) included those showing a complete response to omalizumab 300 mg and group 2 (n=13) included those who received at least 3 doses of omalizumab 450 mg between 2016 and 2018.

The mean Urticaria Activity Score over 7 days decreased from 18,6 to 5,1 and the mean Urticaria Control Test score increase from 8,6 to 12 in group 2 participants after a mean 4,3 courses of omalizumab 450 mg. Of all 13 participants from group 2, 6 of them had a complete response, and 3 a good disease control. Those whose response to treatment was lower had low baseline total IgE levels (<43 IU/mL).

In conclusion, this team demonstrated that higher doses of omalizumab are effective and safe in patients with chronic spontaneous urticaria that is unresponsive to omalizumab 300 mg. Also, they predict that lower baseline total IgE levels might be related to a nonresponse to omalizumab and the need for higher doses.

This document is only available for registered healthcare professionals

Login
Congreso bilastina

Bilastine symposium at the EAACI 2019 congress

By | Articles about Bilastine, New

On the occasion of the celebration of the 38th congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will take place between 1 and 5 June in Lisbon, Faes Farma announces the holding of an important symposium specifically aimed at its antihistamine. own research, bilastine.

This meeting is scheduled for June 2 at 5:30 pm in Hall 5 of the conference venue.

With the title “BILASTINE: A lifetime companion. Value every moment of your life. “, counts as chairman with Prof. Martin Church (UK) and three specialist speakers of international prestige.

The first presentation will be made by Dr. Ralph Mösges (Germany) and will deal with the on-off relationship of patients with their treatments of allergic rhinitis.

The second presentation will be offered by Dr. Marysia Recto (Philippines) and will analyze the needs not covered in patients with urticaria.

Finally, Dr. Zoltán Nóvak (Hungary) will show the need for antihistamine treatments not to affect the life and daily activities of pediatric allergic patients.

You are cordially invited.

You can access the audiovisual contents of other editions in this link.

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR